No CrossRef data available.
Article contents
Paramethoxymethamphetamine (Mitsubishi turbo) abuse: Case report and literature review
Published online by Cambridge University Press: 23 March 2020
Abstract
Paramethoxymethamphetamine and paramethoxyamphetamine (PMMA and PMA) are two so-called designer amphetamines, which appear from time to time on the illegal narcotics market in many countries. They are frequently sold as ecstasy or amphetamine, often mixed with amphetamine or methamphetamine [1, 2]. Paramethoxyamphetamine (PMA) is a hallucinogenic synthetic substituted amphetamine with capable of development of dependence [3]. The purpose of this report is to review the clinical evidence for the potential of abuse of paramethoxyamphetamine. We propouse a case report and literature review.
We conducted a systematic review of the literature with the principal database (PubMed, Enbase, PsychInfo) and we present a case report.
The effects of paramethoxyamphetamine is characterized at the beginning with symptoms like euphoria, derealizzation, psychomotor activation, feeling in tune with surroundings and in love for friends, who come to visual and auditory illusions and hallucinations, paranoid delusion, and violent agitation.
The use of these recreational drugs is especially common among young people participating in rave parties. Occasionally paramethoxymethamphetamine (PMMA) or paramethoxyamphetamine (PMA) are found in street drugs offered as ecstasy. Further research is warranted to replicate our clinical and qualitative observations and, in general, quantitative studies in large samples followed up over time are needed. Methodological limitations, clinical implications and suggestions for future research directions are considered.
The authors have not supplied their declaration of competing interest.
- Type
- e-Poster viewing: Substance related and addictive disorders
- Information
- European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. s875
- Copyright
- Copyright © European Psychiatric Association 2017
Comments
No Comments have been published for this article.